BACKGROUND: Chronic granulomatous disease (CGD) is a primary phagocyte immunodeficiency. It is often accompanied by an exuberant and aberrant inflammatory response, with granulomata and obstruction of the gastrointestinal and genitourinary tracts and inflammatory bowel disease. Although corticosteroids are successful in managing the obstructive and inflammatory disorders of CGD, they are not ordinarily used for the management of infection because of the possibility of further compromising the patient's immune system. OBJECTIVES: To discuss the pros and cons of the use of corticosteroids for the treatment of infections in CGD. METHODS: We describe 2 patients with CGD and refractory infections who were successfully treated with systemic corticosteroids in addition to antimicrobial agents. We also review the medical literature in which corticosteroids have been used for CGD infection. RESULTS: Our cases add to 3 other reports in which antibiotics and corticosteroids were used successfully in patients with CGD. However, in the presence of a potential pathogen, notably, aspergilla, corticosteroids may mask or favor dissemination of the fungus, especially in adults. CONCLUSIONS: Corticosteroids may play an important adjunctive role in CGD refractory infections.
BACKGROUND:Chronic granulomatous disease (CGD) is a primary phagocyte immunodeficiency. It is often accompanied by an exuberant and aberrant inflammatory response, with granulomata and obstruction of the gastrointestinal and genitourinary tracts and inflammatory bowel disease. Although corticosteroids are successful in managing the obstructive and inflammatory disorders of CGD, they are not ordinarily used for the management of infection because of the possibility of further compromising the patient's immune system. OBJECTIVES: To discuss the pros and cons of the use of corticosteroids for the treatment of infections in CGD. METHODS: We describe 2 patients with CGD and refractory infections who were successfully treated with systemic corticosteroids in addition to antimicrobial agents. We also review the medical literature in which corticosteroids have been used for CGD infection. RESULTS: Our cases add to 3 other reports in which antibiotics and corticosteroids were used successfully in patients with CGD. However, in the presence of a potential pathogen, notably, aspergilla, corticosteroids may mask or favor dissemination of the fungus, especially in adults. CONCLUSIONS: Corticosteroids may play an important adjunctive role in CGD refractory infections.
Authors: Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech Journal: J Allergy Clin Immunol Date: 2011-04-17 Impact factor: 10.793
Authors: David M Straughan; Kaitlin C McLoughlin; John E Mullinax; Beatriz E Marciano; Alexandra F Freeman; Victoria L Anderson; Gulbu Uzel; Said C Azoury; Rebecca Sorber; Humair S Quadri; Harry L Malech; Suk See DeRavin; Natasha Kamal; Christopher Koh; Christa S Zerbe; Douglas B Kuhns; John I Gallin; Theo Heller; Steven M Holland; Udo Rudloff Journal: Clin Infect Dis Date: 2018-04-17 Impact factor: 9.079
Authors: Alexandra F Freeman; Beatriz E Marciano; Victoria L Anderson; Gulbu Uzel; Christ Costas; Steven M Holland Journal: Pediatr Infect Dis J Date: 2011-09 Impact factor: 2.129
Authors: Jennifer W Leiding; Alexandra F Freeman; Beatriz E Marciano; Victoria L Anderson; Gulbu Uzel; Harry L Malech; SukSee DeRavin; David Wilks; Aradhana M Venkatesan; Christa S Zerbe; Theo Heller; Steven M Holland Journal: Clin Infect Dis Date: 2011-12-09 Impact factor: 9.079
Authors: Lizbeth Blancas-Galicia; Eros Santos-Chávez; Caroline Deswarte; Quentin Mignac; Isabel Medina-Vera; Ximena León-Lara; Manon Roynard; Selma C Scheffler-Mendoza; Ricardo Rioja-Valencia; Alexandra Alvirde-Ayala; Saul O Lugo Reyes; Tamara Staines-Boone; Jorge García-Campos; Omar J Saucedo-Ramírez; Blanca E Del-Río Navarro; Antonio Zamora-Chávez; Arturo López-Larios; Susana García-Pavón-Osorio; Eugenia Melgoza-Arcos; María R Canseco-Raymundo; Dolores Mogica-Martínez; Marco Venancio-Hernández; Daniel Pacheco-Rosas; Sigifredo Pedraza-Sánchez; Martha Guevara-Cruz; Federico Saracho-Weber; Berenise Gámez-González; Guillermo Wakida-Kuzunoki; Ana R Morán-Mendoza; Ana P Macías-Robles; Roselia Ramírez-Rivera; Eugenia Vargas-Camaño; Carmen Zarate-Hernández; Héctor Gómez-Tello; Emmanuel Ramírez-Sánchez; Fredy Ruíz-Hernández; Domingo Ramos-López; Héctor Acuña-Martínez; María L García-Cruz; María G Román-Jiménez; Marina G González-Villarreal; Aristóteles Álvarez-Cardona; Beatriz A Llamas-Guillén; Jennifer Cuellar-Rodríguez; Alberto Olaya-Vargas; Nideshda Ramírez-Uribe; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Francisco J Espinosa-Rosales; Jeanet Serafín-López; Marco Yamazaki-Nakashimada; Sara Espinosa-Padilla; Jacinta Bustamante Journal: J Clin Immunol Date: 2020-02-10 Impact factor: 8.542